Ningning Ding

594 total citations
22 papers, 177 citations indexed

About

Ningning Ding is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ningning Ding has authored 22 papers receiving a total of 177 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 10 papers in Surgery. Recurrent topics in Ningning Ding's work include Esophageal Cancer Research and Treatment (9 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Ningning Ding is often cited by papers focused on Esophageal Cancer Research and Treatment (9 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Ningning Ding collaborates with scholars based in China, United States and Japan. Ningning Ding's co-authors include Yousheng Mao, Qi Xue, Yushun Gao, Yue Zhao, Feng Li, Lin Yang, Shugeng Gao, Dali Wang, Jinfeng Huang and Bing Luo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Ningning Ding

19 papers receiving 175 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ningning Ding China 9 109 50 47 26 15 22 177
An Jen Chiang Taiwan 11 23 0.2× 26 0.5× 58 1.2× 20 0.8× 27 1.8× 20 241
Francesco Salvestrini Italy 8 77 0.7× 53 1.1× 45 1.0× 23 0.9× 29 1.9× 47 255
Shaohan Yin China 10 72 0.7× 46 0.9× 37 0.8× 147 5.7× 6 0.4× 28 237
Ya‐Fu Cheng Taiwan 6 176 1.6× 80 1.6× 76 1.6× 41 1.6× 56 3.7× 21 280
Manuel Neuberger Germany 9 111 1.0× 45 0.9× 50 1.1× 57 2.2× 35 2.3× 38 232
Heng‐Chung Chen Taiwan 6 157 1.4× 77 1.5× 78 1.7× 39 1.5× 72 4.8× 10 281
Víctor González‐Pérez Spain 7 83 0.8× 66 1.3× 43 0.9× 110 4.2× 6 0.4× 21 285
Inger Marie Løes Norway 9 68 0.6× 220 4.4× 92 2.0× 27 1.0× 48 3.2× 12 335
Wei‐Heng Hung Taiwan 9 205 1.9× 82 1.6× 93 2.0× 42 1.6× 73 4.9× 20 327
Qing Bi China 7 49 0.4× 63 1.3× 26 0.6× 34 1.3× 31 2.1× 8 148

Countries citing papers authored by Ningning Ding

Since Specialization
Citations

This map shows the geographic impact of Ningning Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ningning Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ningning Ding more than expected).

Fields of papers citing papers by Ningning Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ningning Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ningning Ding. The network helps show where Ningning Ding may publish in the future.

Co-authorship network of co-authors of Ningning Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Ningning Ding. A scholar is included among the top collaborators of Ningning Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ningning Ding. Ningning Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Luo, Bing, Pengchao Han, Peng Sun, et al.. (2023). Optimization Design for Federated Learning in Heterogeneous 6G Networks. IEEE Network. 37(2). 38–43. 19 indexed citations
4.
Kim, Sung‐Bae, Eric Van Cutsem, Jaffer A. Ajani, et al.. (2023). Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients. Current Medical Research and Opinion. 40(1). 69–75. 3 indexed citations
5.
Satoh, Taroh, Takashi Kojima, Satoru Motoyama, et al.. (2022). O1-1 Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup. Annals of Oncology. 33. S468–S468.
6.
Cutsem, Eric Van, Kazuaki Kato, Jaffer A. Ajani, et al.. (2022). Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open. 7(4). 100517–100517. 17 indexed citations
7.
Zhao, Kuaile, Sung‐Bae Kim, Ken Kato, et al.. (2022). Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. Journal of Clinical Oncology. 40(4_suppl). 279–279.
8.
Cutsem, Eric Van, Ken Kato, Jaffer A. Ajani, et al.. (2022). Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).. Journal of Clinical Oncology. 40(4_suppl). 268–268. 1 indexed citations
9.
Zhao, Yue, Yousheng Mao, Jie He, et al.. (2020). Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non–small-cell Lung Cancer: A Propensity Score Matching Study. Clinical Lung Cancer. 22(2). e201–e210. 17 indexed citations
10.
11.
Li, Feng, et al.. (2018). The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis. International Journal of Surgery. 60. 88–100. 12 indexed citations
12.
Yang, Lin, Yikun Yang, Peiqing Ma, et al.. (2018). Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy. Journal of Thoracic Disease. 10(9). 5308–5317. 21 indexed citations
13.
Ding, Ningning, Yousheng Mao, Shugeng Gao, et al.. (2018). Predictors of lymph node metastasis and possible selective lymph node dissection in clinical stage IA non-small cell lung cancer. Journal of Thoracic Disease. 10(7). 4061–4068. 29 indexed citations
14.
Ding, Ningning, Yousheng Mao, Jie He, et al.. (2017). Experiences in the management of anastomotic leakages and analysis of the factors affecting leakage healing in patients with esophagogastric junction cancer. Journal of Thoracic Disease. 9(2). 386–391. 10 indexed citations
15.
Yang, Yikun, Yousheng Mao, Lin Yang, et al.. (2017). Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. Journal of Thoracic Disease. 9(12). 5267–5277. 10 indexed citations
16.
Ding, Ningning & Yousheng Mao. (2016). [Advances in Lymph Node Metastasis and the Modes of Lymph Node 
Dissection in Early Stage Non-small Cell Lung Caner].. SHILAP Revista de lepidopterología. 19(6). 359–63. 3 indexed citations
17.
18.
Ding, Ningning & Yousheng Mao. (2015). [Advances of mediastinal lymph node metastasis and the extent of lymph node 
dissection in patients with stage T1 non-small cell lung cancer].. SHILAP Revista de lepidopterología. 18(1). 34–41. 1 indexed citations
19.
Liu, Ying, et al.. (2015). [Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].. PubMed. 44(4). 262–5. 2 indexed citations
20.
Mao, Yousheng, Jie He, Shugeng Gao, et al.. (2014). [Exploration of lymph node metastasis and appropriate lymph node dissection modes in patients with clinical stage I non-small cell lung cancer].. PubMed. 36(7). 536–40. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by An Jen Chiang Breakdown of academic impact, for papers by Francesco Salvestrini Breakdown of academic impact, for papers by Shaohan Yin Breakdown of academic impact, for papers by Ya‐Fu Cheng Breakdown of academic impact, for papers by Manuel Neuberger Breakdown of academic impact, for papers by Heng‐Chung Chen Breakdown of academic impact, for papers by Víctor González‐Pérez Breakdown of academic impact, for papers by Inger Marie Løes Breakdown of academic impact, for papers by Wei‐Heng Hung Breakdown of academic impact, for papers by Qing Bi
Rankless by CCL
2026